Study: Aligning EMA, HTA facilitates process, but clarity needed
By Nuala Moran
Friday, June 27, 2014
LONDON The EMA published the conclusions of a first attempt to bring its pan-European assessments of absolute efficacy into line with the needs of national health technology assessment (HTA) bodies that are responsible for making judgements on relative efficacy of drugs, to feed into reimbursement decisions at a member state level.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.